Business Wire

MI-EATON

Share
Eaton Leverages Cylinder Deactivation and Exhaust Thermal Management Technologies to Reduce Commercial Vehicle Emissions

Power management company Eaton today announced its Vehicle Group has demonstrated cylinder deactivation (CDA) as an effective technology for meeting future global emissions requirements for diesel-engine powered commercial vehicles. To date, the technology has been evaluated with a close-coupled selective catalytic reduction (SCR) aftertreatment system with and without a 48-volt electric heater.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211116005234/en/

“Our CDA technology has proven it can help our customers meet increasingly strict emissions regulations for diesel engines,” said Christopher Mancuso, business unit director, Engine Air Management, Eaton’s Vehicle Group. “This comes at a time when many global manufacturers are determining what technologies they will leverage in next-generation vehicles to reduce harmful emissions.”

New emissions regulations spearheaded by the California Air Resources Board (CARB), U.S. Environmental Protection Agency (EPA) and European Commission (EC) are slated for adoption in coming years. These agencies, in concert with other national and international regulators, seek to significantly reduce greenhouse gas (GHG) emissions and harmful air pollutants produced primarily by heavy-duty trucks, vans and buses.

Rapid catalyst warm-up essential

Eaton partnered with the Southwest Research Institute (SwRI), one of the oldest and largest independent, nonprofit, applied research and development organizations in the U.S., to demonstrate the feasibility of its Vehicle Group’s technology. The findings demonstrate that using CDA and a close-coupled SCR catalyst reduced both nitrous oxide (NOx) and carbon dioxide (CO2 ) emissions with fuel consumption savings of up to 40% at idle.

Previous results utilizing CDA and a close-coupled SCR catalyst demonstrated compliance to forthcoming U.S. regulations for NOx and CO2 emissions for diesel commercial vehicles. Testing with the new low-load cycle (LLC) resulted in a 5% drop in CO2 while dramatically reducing NOx. The assessment was developed by CARB to replicate real-world urban tractor and vocational vehicle operations at low engine loads.

Eaton’s 2021 testing with SwRI showed further advancement, dropping NOx levels by 99.4% on the composite federal test procedure (FTP) and lowering the LLC NOx to well within current guidelines. Notably, using the same aftertreatment system with the addition of a 48-volt electric heater located upstream of the SCR further achieved a reduction in CO2 .

CDA technology can benefit vehicle manufacturers facing tightening emissions standards in Europe as well. The next set of requirements, known as Euro VII for heavy-duty trucks, is targeted for the second part of the decade. In the U.S., CARB is introducing more stringent regulations as soon as 2024, while the EPA has circled 2027 to begin applying stricter emissions limits on new-model heavy-duty vehicles. Collectively, these standards are designed to reduce tailpipe NOx emissions up to 90%, accelerating the need for global engine manufacturers to employ additional emissions-reduction strategies such as electric catalyst heating. This technology is an example of how Eaton is progressing toward achieving its 2030 Sustainability Targets . By 2030, the company aims to reduce emissions from its solutions and throughout its value chain by 15%.

Eaton’s mission is to improve the quality of life and the environment through the use of power management technologies and services. We provide sustainable solutions that help our customers effectively manage electrical, hydraulic, and mechanical power – more safely, more efficiently, and more reliably. Eaton’s 2020 revenues were $17.9 billion, and we sell products to customers in more than 175 countries. We have approximately 85,000 employees. For more information, visit www.eaton.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 08:00:00 CET | Press release

After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support for Japanese research to the new IDEAL Japan initiativeThe “Innovation Debiopharm Academia Life Science” (IDEAL) program is designed to financially and scientifically support academic research with the goal of accelerating the translation of innovation into novel therapies for patientsThe first IDEAL Japan agreement was signed with the National Cancer Center Japan Research Institute Laboratory of Genome Stability Maintenance to advance research in early-stage colon cancer Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approa

Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release

MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release

Over 30 Million Users Benefit From Ant International’s Bettr Credit Tech Solutions18.11.2025 04:35:00 CET | Press release

Powering the Next Wave of MSME Growth with Digital Platforms in Emerging MarketsThere was a threefold year-on-year increase in eligible customers reached through partners using Bettr's credit tech solutions by the end of October 2025.The solution features an AI-driven, alternative-data-powered credit engine that can help partner platforms to cut credit policy deployment from weeks to minutes.Partnership with Dock, a leading Brazilian payments and banking technology provider, will expand the deployment of Bettr’s credit tech solutions. Bettr, a leading provider of inclusive financial services and technology business under Ant International, today announced the launch of its proprietary tailored, one-stop credit tech solutions designed to help digital platforms build and scale their lending businesses to better serve micro, small and medium enterprises (MSMEs) in emerging markets. Bettr's credit tech solutions supported over 30 million customers to gain access to credit services through

Ant International Deepens Participation in Project Ensemble as New Architecture Community Member18.11.2025 04:00:00 CET | Press release

Ant International has been a participant in the Ensemble Sandbox since 2024 Ant International today announced it has joined Project Ensemble’s Architecture Community to support the design and advancement of Hong Kong’s tokenisation ecosystem. As a Community member, it will be more involved in defining industry standards and supporting the development of Hong Kong’s tokenisation market, together with the Hong Kong Monetary Authority (HKMA) and leading peers. A fintech representative on the Community, Ant International will also contribute its technological and innovation capabilities in tokenisation to support broader industry adoption. This comes at a time when Project Ensemble reaches a new milestone with EnsembleTX, which will see it move from sandbox experiments to live market use within a pilot environment. Through EnsembleTX, Ant International will continue to broaden its partnerships with banks and other committee members, contributing to real-world use cases of tokenisation in r

Celltrion Announces European Commission Approval of Additional Line Extension for Omlyclo™ 300mg18.11.2025 03:51:00 CET | Press release

Omlyclo™ (omalizumab) is the first and only omalizumab biosimilar approved in EuropeOmlyclo™ 300 mg/2ml prefilled syringe (PFS) presentation is now approved in EU offering a simpler dosing schedule and improved patient adherence The European Commission (EC) has granted a line extension in the European Union (EU) for Celltrion’s Omlyclo™ (omalizumab), Europe’s first and only omalizumab biosimilar, for the 300 mg/2ml prefilled syringe (PFS).The European Commission (EC) approved Omlyclo™ 75 mg/0.5ml and 150mg/1ml solution for injection in pre-filled syringe in May 2024. Omlyclo™ is indicated for the treatment of patients with allergic asthma, chronic spontaneous urticaria (CSU) and chronic rhinosinusitis with nasal polyps (CRSwNP). “The additional strength of Omlyclo™ 300mg can significantly decrease the frequency of injections, and reduce injection burden and discomfort, without compromising efficacy and safety,” said Nam Lee, Vice President of Global Medical Affairs at Celltrion. “These

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye